Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Short-term Investments (2022 - 2025)

Gossamer Bio's Short-term Investments history spans 4 years, with the latest figure at $99.2 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 60.07% year-over-year to $99.2 million; the TTM value through Dec 2025 reached $99.2 million, down 60.07%, while the annual FY2025 figure was $99.2 million, 60.07% down from the prior year.
  • Short-term Investments reached $99.2 million in Q4 2025 per GOSS's latest filing, down from $171.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $298.6 million in Q3 2024 to a low of $99.2 million in Q4 2025.
  • Average Short-term Investments over 4 years is $189.6 million, with a median of $179.0 million recorded in 2025.
  • Peak YoY movement for Short-term Investments: soared 113.88% in 2024, then plummeted 60.07% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $143.7 million in 2022, then surged by 83.93% to $264.3 million in 2023, then fell by 6.0% to $248.4 million in 2024, then tumbled by 60.07% to $99.2 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Short-term Investments are $99.2 million (Q4 2025), $171.3 million (Q3 2025), and $186.6 million (Q2 2025).